GlassScriptPhysician profile
Michael J Robbins
NPI 1477665420
$4,533.58
in general payments reported to CMS, 2019-2025
34 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $422 · 2021: $729 · 2022: $1,504 · 2023: $240 · 2024: $36.32 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $381.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,469.26 | 2022-2023 | Ha Minuteman G3-R |
| Relievant Medsystems, INC. | $566.62 | 2021 | |
| Boston Scientific Corporation | $424.83 | 2020-2023 | |
| Collegium Pharmaceutical, INC. | $239.38 | 2019-2020 | |
| Medtronic, INC. | $164.22 | 2022-2024 | Intellis Adaptivestim |
| Arbor Pharmaceuticals, INC. | $139.40 | 2019-2020 | |
| Mdd US Operations, LLC | $128.72 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $121.09 | 2019-2023 | Ztlido |
| Nevro Corp. | $114.63 | 2019 | |
| Abbott Laboratories | $114.52 | 2019-2020 | |
| Saluda Medical Americas, INC. | $102.70 | 2023-2025 | Evoke, Evoke Scs |
| Merz North America, INC. | $88.70 | 2019-2020 | |
| Daiichi Sankyo INC. | $83.25 | 2019 | |
| Vertiflex, INC. | $82.39 | 2019 | |
| Sentynl Therapeutics, INC. | $79.76 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.17 | 2019 | |
| Amgen INC. | $56.58 | 2019 | |
| Vertos Medical, INC. | $54.62 | 2021 | |
| Lilly USA, LLC | $51.29 | 2019 | |
| Kaleo, INC. | $45.05 | 2019 | |
| Vertical Pharmaceuticals, LLC | $38.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $38.09 | 2019 | |
| Medtronic USA, INC. | $36.75 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $34.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.14 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.06 | 2019 | |
| Inspire Medical Systems, INC. | $25.04 | 2025 | Inspire |
| Fidia Pharma USA INC. | $22.08 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.69 | 2019 | |
| Tersera Therapeutics LLC | $18.14 | 2019 | |
| Biodelivery Sciences International, INC. | $16.46 | 2019 | |
| Shionogi INC | $13.56 | 2019 | |
| Merck Sharp & Dohme LLC | $13.55 | 2024 | Bridion |
| Horizon Therapeutics Plc | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.